Compare Stocks: LIPO, ALVOW, APLMW, and ARAV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVOW Alvotech	$0.15	$0.20	$0.12 ▼ $3.00	N/A	N/A	5,049 shs	N/A
APLMW Apollomics	$0.02 +16.4%	$0.02	$0.00 ▼ $0.23	N/A	N/A	64,867 shs	72,827 shs
ARAV Aravive	$0.04	$0.04	$0.04 ▼ $2.46	N/A	N/A	N/A	N/A
LIPO Lipella Pharmaceuticals	$0.00	$0.07	$0.00 ▼ $0.65	$1K	1.36	31,837 shs	202 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVOW Alvotech	0.00%	0.00%	-11.71%	-24.95%	-88.54%
APLMW Apollomics	+16.35%	+17.09%	+54.17%	+12.12%	-29.92%
ARAV Aravive	0.00%	0.00%	0.00%	0.00%	0.00%
LIPO Lipella Pharmaceuticals	0.00%	-99.39%	-99.72%	-99.33%	-99.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVOW Alvotech	$0.15	$0.20	$0.12 ▼ $3.00	N/A	N/A	5,049 shs	N/A
APLMW Apollomics	$0.02 +16.4%	$0.02	$0.00 ▼ $0.23	N/A	N/A	64,867 shs	72,827 shs
ARAV Aravive	$0.04	$0.04	$0.04 ▼ $2.46	N/A	N/A	N/A	N/A
LIPO Lipella Pharmaceuticals	$0.00	$0.07	$0.00 ▼ $0.65	$1K	1.36	31,837 shs	202 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVOW Alvotech	0.00%	0.00%	-11.71%	-24.95%	-88.54%
APLMW Apollomics	+16.35%	+17.09%	+54.17%	+12.12%	-29.92%
ARAV Aravive	0.00%	0.00%	0.00%	0.00%	0.00%
LIPO Lipella Pharmaceuticals	0.00%	-99.39%	-99.72%	-99.33%	-99.97%

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVOW Alvotech	N/A	N/A	N/A
APLMW Apollomics	N/A	N/A	N/A
ARAV Aravive	N/A	N/A	N/A
LIPO Lipella Pharmaceuticals	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVOW Alvotech	$559.42M	N/A	N/A	N/A	N/A	N/A
APLMW Apollomics	$8.50M	N/A	N/A	N/A	N/A	N/A
ARAV Aravive	N/A	N/A	N/A	N/A	N/A	N/A
LIPO Lipella Pharmaceuticals	$536.36K	0.00	N/A	N/A	$1.59 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVOW Alvotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	8/19/2026 (Estimated)
APLMW Apollomics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/24/2026 (Estimated)
ARAV Aravive	N/A	-$0.90	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LIPO Lipella Pharmaceuticals	-$5.02M	-$2.42	N/A	N/A	N/A	-988.83%	-224.08%	-172.88%	9/2/2026 (Estimated)

Latest LIPO, ALVOW, APLMW, and ARAV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
9/2/2026	N/A	LIPO Lipella Pharmaceuticals	-$1.28	N/A	N/A	N/A	$0.15 million	N/A
8/19/2026	N/A	ALVOW Alvotech	-$0.0526	N/A	N/A	N/A	$103.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVOW Alvotech	N/A	N/A	N/A	N/A	N/A
APLMW Apollomics	N/A	N/A	N/A	N/A	N/A
ARAV Aravive	N/A	N/A	N/A	N/A	N/A
LIPO Lipella Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVOW Alvotech	N/A	N/A	N/A
APLMW Apollomics	N/A	N/A	N/A
ARAV Aravive	N/A	N/A	N/A
LIPO Lipella Pharmaceuticals	N/A	6.21	6.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVOW Alvotech	N/A
APLMW Apollomics	N/A
ARAV Aravive	35.80%
LIPO Lipella Pharmaceuticals	74.31%

Insider Ownership

Company	Insider Ownership
ALVOW Alvotech	N/A
APLMW Apollomics	N/A
ARAV Aravive	60.40%
LIPO Lipella Pharmaceuticals	32.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVOW Alvotech	4	N/A	N/A	Not Optionable
APLMW Apollomics	59	N/A	N/A	Not Optionable
ARAV Aravive	20	N/A	N/A	No Data
LIPO Lipella Pharmaceuticals	4	4.62 million	3.03 million	Not Optionable

LIPO, ALVOW, APLMW, and ARAV Headlines

Recent News About These Companies

Lipella Pharmaceuticals Begins Chapter 11 Bankruptcy Restructuring Process

March 31, 2026 | tipranks.com

Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11

March 30, 2026 | globenewswire.com

Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus

September 18, 2025 | finance.yahoo.com

Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus

September 15, 2025 | prnewswire.com

LIPO - Lipella Pharmaceuticals Inc Ordinary Shares Dividends | Morningstar

July 18, 2025 | morningstar.comM

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - Morningstar

June 27, 2025 | morningstar.comM

Lipella Pharmaceuticals delisted from Nasdaq, explores relisting options amid ongoing operations

June 27, 2025 | bizjournals.com

Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting

June 26, 2025 | finanznachrichten.de

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting

June 25, 2025 | globenewswire.com

Nasdaq delists Lipella Pharmaceuticals over rule violations

June 22, 2025 | investing.com

Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

June 21, 2025 | finanznachrichten.de

Lipella stock tumbles after Nasdaq delisting over rule violations

June 20, 2025 | in.investing.com

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

June 20, 2025 | globenewswire.com

Lipella Pharmaceuticals Inc. Announces Issuance of U.S. Patent for Advanced Detection Method of Interstitial Cystitis

June 17, 2025 | quiverquant.comQ

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

June 17, 2025 | globenewswire.com

Lipella Pharmaceuticals extends manufacturing pact with Cook MyoSite

June 5, 2025 | investing.com

Lipella Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite

June 4, 2025 | contractpharma.comC

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

June 4, 2025 | prismmediawire.comP

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

June 4, 2025 | globenewswire.com

Lipella Pharmaceuticals to appeal Nasdaq noncompliance warning

May 20, 2025 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIPO, ALVOW, APLMW, and ARAV Company Descriptions

Alvotech NASDAQ:ALVOW

$0.15 0.00 (0.00%)

As of 08/5/2026

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apollomics NASDAQ:APLMW

$0.02 +0.00 (+16.35%)

As of 08/6/2026 03:59 PM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)

As of 08/5/2026

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Lipella Pharmaceuticals NASDAQ:LIPO

$0.0002 0.00 (0.00%)

As of 08/6/2026 01:01 PM Eastern

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LIPO, ALVOW, APLMW, and ARAV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LIPO, ALVOW, APLMW, and ARAV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIPO, ALVOW, APLMW, and ARAV Company Descriptions

Alvotech NASDAQ:ALVOW

Apollomics NASDAQ:APLMW

Aravive NASDAQ:ARAV

Lipella Pharmaceuticals NASDAQ:LIPO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LIPO, ALVOW, APLMW, and ARAV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LIPO, ALVOW, APLMW, and ARAV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIPO, ALVOW, APLMW, and ARAV Company Descriptions

Alvotech NASDAQ:ALVOW

Apollomics NASDAQ:APLMW

Aravive NASDAQ:ARAV

Lipella Pharmaceuticals NASDAQ:LIPO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools